Compare JPMorgan Chase & Co (JPM) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Tempus AI — how do they compare? JPMorgan Chase & Co trades at $331.85 (market cap $880.98B), while Tempus AI trades at $70.03 (market cap $12.58B). The key difference: JPMorgan Chase & Co is far larger — about 70× Tempus AI's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Tempus AI for 22 Days on average.
| JPM | TEM | |
|---|---|---|
Market Cap | $880.98B | $12.58B |
Volume | 7,721,661 | 7,444,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $365.18 | $99.28 |
52-Week Low | $282.84 | $41.55 |
Typical Hold Time | 127 Days | 22 Days |
Enterprise Value | $1.82T | $13.21B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% on the day, with a bearish technical signal. The stock shows strong fundamentals, with a P/E of 14.12 and net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 was a miss. Analyst consensus is a Moderate Buy with a $373.18 price target, implying potential upside. Cash flow trends show significant financing activities offsetting negative operating cash flows.
The outlook for JPM is positive based on robust profitability and analyst support, but risks include volatile cash flows, geopolitical tensions affecting banking sectors, and CEO warnings on economic challenges. The stock's current price near support at $327 suggests a potential entry point for long-term investors, though near-term bearish technicals warrant caution.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
